Farmas USA

PSTI o como soñar con una mini divergencia en semanal.

de momento no hay que pagar comisión ni ponerle stop loss a los sueños....¿o si?.

psti, esta gráfica mejor y nada de lo anterior.

ONVO

Información del folleto de oferta de acciones

The price to the public in the Offering is $4.50 per share, and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $4.23 per share.

While complete financial information and operating data as of and for such period are not yet available, based on the information and data currently available, the Company’s management preliminarily estimates that for the three months ended June 30, 2013 its net loss was approximately $(3.8) million, compared to a net loss of $(16.1) million for the three months ended March 31, 2013. Additionally, management estimates that as of June 30, 2013, the Company had cash and cash equivalents of approximately $12.8 million and an accumulated deficit of approximately $(70.1) million, as compared to $15.6 million and $(66.4) million, respectively, at March 31, 2013. At June 30, 2013, management estimates negative cash flow from operations was approximately $2.7 million, as compared to $2.8 million for the three months ended March 31, 2013

The Company anticipates using the net proceeds from this offering for general corporate purposes, including research and development, the development and commercialization of its products,
general administrative expenses, license or technology acquisitions, and working capital and capital expenditures.

VNDA

Por lo visto es una noticia que no es nueva; va apareciendo periódicamente desde hace un mes.

Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (Nasdaq:VNDA) and certain of its officers. This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws.

On June 19, 2013, The Street published an article raising doubts about the quality and efficacy of Vanda's clinical trial procedure and test data. Among other issues, the article noted multiple changes in the primary endpoint over the course of the trials, including a change just one month before study results were published to a new primary endpoint that has allegedly never been used before in sleep-drug clinical trials, nor was it endorsed by the FDA. The article also states that Vanda was forced to cut patient enrollment in the clinical trials in half because an insufficient number of totally blind patients with Non-24 could not be identified, and that ultimately less than 5% of the patients enrolled in the trials suffered from Non-24 according to the "textbook definition" of the disease. On this news, Vanda shares declined $2.41 per share or more than 22%, to close at $8.51 per share on June 19, 2013.

http://globenewswire.com/news-release/2013/08/02/564365/10043255/en/Pomerantz-Law-Firm-Reminds-Shareholders-With-Losses-on-Their-Investment-in-Vanda-Pharmaceuticals-Inc-of-Class-Action-Lawsuit-and-Upcoming-Deadline-VNDA.html

Del Bastardo, twits de estos últimos días , no se si en respuesta a otros o que ...
el último el mas reciente:

"$VNDA, FDA And $500K Bonus Paid To A Mystery Regulatory Consultant "
http://www.thestreet.com/story/11994676/1/vanda-fda-and-500k-bonus-paid-to-a-mystery-regulatory-consultant.html

"$VNDA claims tasi is new class of drug, so FDA compelled to convene adcomm. Um… Yervoy, Kalydeco, Zytiga all new drug class, no adcomms.·"

"Besides, tasi is not a new drug class. It's a melatonin receptor agonist! You can buy melatonin everywhere."

"Does tasimelteon have a companion chronodiagnostic? $VNDA"

"I missed this y'day. $VNDA CEO coins new description for tasimelteon: It's a "chronotherapeutic." Time travel, here we come!"

If tasimelteon is a "chronotherapeutic" then an alarm clock is a "chronotherapeutic device."

Suena a que no le gusta VNDA para nada diria yo ...

VNDA

http://seekingalpha.com/article/1599712-biocryst-the-next-orphan-drug-1b-company?source=google_news

Una que han comentado por aqui,s2

Interesting data from Eisai presentation:

Eisai Efforts "Toward Future Growth" and "Public Awareness" for Belviq Since launch:

- Moe than 14,000 patients registered for Belviq support program.
- Continued provision of 15-day free trial voucher and savings cards for patients with and without commercial overage.
- More than 60% of initial prescriptions are for voucher programs leading to early patient experience and treatment.
- Approximately 30% coverage of commercial lives with formulary access in ongoing contracts with major plans.
- Seek 50% access coverage by end of FY 2013, earlier than the original plan.
- As of 7/19/13 approximately 3900 physicians have written prescriptions for Belviq.
- News converage of Belviq availability reached 300 million people. Over, 100 TV segments, over 300 news sites with press release reaching 74 million readers; 17 million radio listeners, featured in Time Square and Las Vegas "Jumbotron."
- Belviq website for healthcare professionals has expereinced higher than expected traffic: Over 100,000 unique visits in the first month.

ARNA

MJNA

en observación, se mueve otra vez el tema de la marihuana en USA. aun recuerdo el 250% que le saque. no sera lo mismo pero puede crecer el mercado con los nuevos estados que se suman a la legalización.
http://www.marketwatch.com/story/want-a-marijuana-prescription-get-in-line-2013-07-26?link=sfmw